10.71

0.65% -0.11

Tyra Biosciences Inc (TYRA)

Overview News Price History Option Chain Financials Discussions Forecast

Tyra Biosciences Inc stock is traded at $10.71, with a volume of 21,888. It is down -0.65% in the last 24 hours and down -12.24% over the past month. Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

Previous Close:

$10.82

Open:

$10.81

24h Volume:

21,888

Relative Volume:

0.09

Market Cap:

$545.50M

Revenue:

Net Income/Loss:

$-83.74M

P/E Ratio:

-6.6522

EPS:

-1.61

Net Cash Flow:

$-64.98M

1W Performance:

-2.80%

1M Performance:

-12.24%

6M Performance:

-49.39%

1Y Performance:

-42.64%

1-Day Range:

$10.59

$10.94

1-Week Range:

$9.93

$11.79

52-Week Range:

$9.93

$29.60

Tyra Biosciences Inc Stock (TYRA) Company Profile

Name

Tyra Biosciences Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

(619) 728-4760

Address

2656 STATE STREET, CARLSBAD

Employee

Twitter

Next Earnings Date

2024-08-08

Latest SEC Filings

TYRA's Discussions on Twitter

Compare TYRA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TYRA Tyra Biosciences Inc	10.75	545.50M	0	-83.74M	-64.98M	-1.61
VRTX Vertex Pharmaceuticals Inc	502.30	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	685.47	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	578.42	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.49	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.97	26.76B	3.32B	-860.46M	-1.04B	-8.32

Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-25	Initiated	UBS	Buy
Oct-18-24	Upgrade	BofA Securities	Neutral → Buy
Aug-15-24	Initiated	Piper Sandler	Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Jun-30-23	Initiated	Wedbush	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Jun-23-22	Initiated	H.C. Wainwright	Buy
Mar-08-22	Upgrade	Jefferies	Hold → Buy
Nov-08-21	Downgrade	Jefferies	Buy → Hold
Oct-11-21	Initiated	BofA Securities	Buy
Oct-11-21	Initiated	Cowen	Outperform
Oct-11-21	Initiated	Jefferies	Buy

View All

Tyra Biosciences Inc Stock (TYRA) Latest News

07:20 AM

(TYRA) On The My Stocks Page - Stock Traders Daily

07:20 AM

Mar 11, 2025

Tyra Biosciences (TYRA) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Mar 11, 2025

Mar 10, 2025

Tyra Biosciences stock hits 52-week low at $10.62 amid market challenges - Investing.com Australia

Mar 10, 2025

Tyra Biosciences stock hits 52-week low at $10.62 amid market challenges By Investing.com - Investing.com South Africa

Mar 10, 2025

Rhumbline Advisers Grows Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World

Mar 10, 2025

Mar 04, 2025

BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight - GlobeNewswire Inc.

Mar 04, 2025

Tyra Biosciences, Inc. (NASDAQ:TYRA) Sees Large Growth in Short Interest - Defense World

Mar 04, 2025

Mar 03, 2025

Advanced Urothelial Carcinoma Clinical Trial Pipeline - GlobeNewswire

Mar 03, 2025

Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire

Mar 03, 2025

Brokerages Set Tyra Biosciences, Inc. (NASDAQ:TYRA) Price Target at $30.50 - Defense World

Mar 01, 2025

Feb 28, 2025

Tyra Biosciences (NASDAQ:TYRA) Hits New 12-Month LowTime to Sell? - MarketBeat

Feb 28, 2025

Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.50 Consensus Target Price from Analysts - MarketBeat

Feb 28, 2025

Feb 27, 2025

Tyra Biosciences stock hits 52-week low at $11.88 amid market shifts - Investing.com Canada

Feb 27, 2025

Feb 20, 2025

(TYRA) Investment Analysis - Stock Traders Daily

Feb 20, 2025

Feb 19, 2025